Michael Thase

0475 Long-Term Medical Treatment of Chronic Insomnia: A Further Exploration of Maintenance Regimens

Michael Perlis, Knashawn Morales, Iván Vargas, Michael Grandner et autres

Abstract Introduction At present the uncodified standard for the medical treatment of insomnia is to use hypnotics as needed or intermittently (3-5x per week). While both approaches are dose sparing, neither may provide for the highest rate of treatment responding. Based on …

us (code pays fourni par la source)

The STAR*D Data Remain Strong: Reply to Pigott et al.

Augustus John Rush, Madhukar H. Trivedi, Maurizio Fava, Michael Thase et autres

Insomnia

Michael Lloyd Perlis, Donn A. Posner, Dieter Wilhelm Riemann, Célyne Bastien et autres

us, de, ca (code pays fourni par la source)

P.094 Evaluate effects of pimavanserin on anxious depression in patients with major depressive disorder - secondary analysis of the CLARITY Study

George I. Papakostas, Maurizio Fava, Marlene P. Freeman, Richard Charles Shelton et autres

us (code pays fourni par la source)

General Predictors and Moderators of Depression Remission: A VAST-D Report

Sidney Zisook, Gary R. Johnson, Ilanit Tal, Paul B. Hicks et autres

OBJECTIVE: Almost two-thirds of patients with major depressive disorder do not achieve remission with initial treatments. Thus, identifying and providing effective, feasible, and safe "next-step" treatments are clinical imperatives. This study explores patient baseline features that might help clinicians select between commonly …

us (code pays fourni par la source)

50 Adjunctive Buprenorphine/Samidorphan Combination in Patients with Major Depressive Disorder: Phase 3 Long-term Extension Study Results

Michael Thase, Arielle D. Stanford, Asli Cinar Memisoglu, William F. Martin et autres

Abstract Introduction Buprenorphine/samidorphan (BUP/SAM), a combination of BUP (a µ-opioid receptor partial agonist and κ-antagonist) and SAM (a sublingually bioavailable µ-opioid antagonist), is an investigational opioid system modulator for depression. BUP/SAM has shown efficacy versus placebo as an adjunctive treatment for major …

us (code pays fourni par la source)

2018 American Society of Consultant Pharmacists Annual Meeting & Exhibition.

Mary Bridgeman, Donna Prete, Nicole Rolston, Daniel Abazia et autres

. Industry support is indicated, where applicable. Presenting author is in italics. The poster abstract presentation is supported by the ASCP Foundation.

Venlafaxine and Desvenlafaxine

Michael Thase

Durability of treatment response to zolpidem with three different maintenance regimens: a preliminary study

Michael Lloyd Perlis, Michael A. Grandner, Jarcy Zee, Erin Bremer et autres

us (code pays fourni par la source)

Safety and Efficacy of Synchronized Transcranial Magnetic Stimulation for the Treatment of Major Depressive Disorder

Andrew F. Leuchter, Bill Phillips, Yi Jin, Ian A. Cook et autres

us (code pays fourni par la source)

Efficacy and safety of duloxetine 60 mg once daily in major depressive disorder: a review with expert commentary

Susan G. Ball, Durisala Desaiah, Qi Zhang, Michael Thase et autres

OBJECTIVE: Major depressive disorder (MDD) is a significant public health concern and challenges health care providers to intervene with appropriate treatment. This article provides an overview of efficacy and safety information for duloxetine 60 mg/day in the treatment of MDD, including its …

us, gb (code pays fourni par la source)

PMH39 Identifying Disease-Defining Concepts Using Spontaneous and Probed Responses From Semi-Structured Qualitative Interviews in Patients With Major Depressive Disorder

Kelly P. McCarrier, Lucy Abraham, Linda L. Carpenter, Linda S. Deal et autres

gb, us, in (code pays fourni par la source)